Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals.

Antiviral therapy - 1 Jan 2016

Nguyen Linh Thuy, Hall Naomi, Sheerin Dylan, Carr Michael, De Gascun Cillian F

Abstract excerpt

BACKGROUND: Direct-acting antivirals (DAAs) have significantly improved the treatment response in HCV chronic infection with higher potency and better tolerance. We established the prevalence of naturally occurring NS5A and NS5B inhibitor resistance-associated mutations (RAMs) in HCV genotype (GT)-1 chronically infected individuals in Ireland. METHODS: In a multicentre cohort study, employing sequencing-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, Viral

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Ireland

Share to Mutagenesis, Insertional

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 26789637
DOI: 10.3851/IMP3025

Genes

IFNL3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals.PMID 26789637Read ↗

Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.Semantic proximity Read ↗

World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents.Semantic proximity Read ↗

Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus InfectionSemantic proximity Read ↗

Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.Semantic proximity Read ↗

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.Semantic proximity Read ↗

Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals.Semantic proximity Read ↗

HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.Semantic proximity Read ↗

The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures.Semantic proximity Read ↗

Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience.Semantic proximity Read ↗

Update on hepatitis C virus resistance to direct-acting antiviral agents.Semantic proximity Read ↗

Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.Semantic proximity Read ↗

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.